Stock-Based Compensation (Tables)
|
3 Months Ended |
12 Months Ended |
Mar. 31, 2026 |
Sep. 30, 2025 |
| Share-Based Payment Arrangement [Abstract] |
|
|
| Schedule of Activity in the Company’s RSUs |
A
summary of activity in the Company’s RSUs for the six months ended March 31, 2026 is as follows:
Schedule
of Activity in the Company's RSUs
| | |
Number
of units | | |
Weighted-
Average Grant
Date Fair
Value per
Unit | |
| Outstanding at September 30, 2025 | |
| 954,562 | | |
$ | 42.10 | |
| Granted | |
| 112,326 | | |
| 3.14 | |
| Forfeited | |
| (20,741 | ) | |
| 12.69 | |
| Vested | |
| (486,415 | ) | |
| 36.16 | |
| Outstanding at March 31, 2026 | |
| 559,732 | | |
| 45.08 | |
|
A
summary of activity in the Company’s RSUs for the year ended September 30, 2025 is as follows:
Schedule
of Activity in the Company’s RSUs
| | |
Number of
units | | |
Weighted-
Average
Grant Date
Fair Value
per Unit | |
| | |
| | |
| |
| Outstanding at September 30, 2024 | |
| 446,318 | | |
$ | 79.30 | |
| Issued | |
| 1,103,679 | | |
| 9.64 | |
| Forfeited | |
| (4,776 | ) | |
| 33.59 | |
| Vested | |
| (590,622 | ) | |
| 9.58 | |
| Outstanding at September 30, 2025 | |
| 954,599 | | |
| 42.11 | |
|
| Schedule of Activity in the Company’s RSAs |
A
summary of activity in the Company’s RSAs for the six months ended March 31, 2026 is as follows:
Schedule
of Activity in the Company's RSAs
| | |
Number
of
shares | | |
Weighted-
Average
Grant
Date
Fair
Value
per
Share | |
| | |
| | |
| |
| Outstanding at September 30, 2025 | |
| 487,250 | | |
$ | 7.00 | |
| Vested | |
| (71,000 | ) | |
| 7.00 | |
| Outstanding at March 31, 2026 | |
| 416,250 | | |
| 7.00 | |
|
A
summary of activity in the Company’s RSAs for the year ended September 30, 2025 is as follows:
Schedule
of Activity in the Company’s RSAs
| | |
Number of
units | | |
Weighted-
Average
Grant Date
Fair Value
per Share | |
| | |
| | |
| |
| Outstanding at September 30, 2024 | |
| — | | |
$ | — | |
| Issued | |
| 510,000 | | |
| 7.00 | |
| Vested | |
| (22,750 | ) | |
| 7.00 | |
| Outstanding at September 30, 2025 | |
| 487,250 | | |
| 7.00 | |
|
| Schedule of Stock Option Activity |
Stock
option activity for the six months ended March 31, 2026 is as follows:
Schedule of Stock Option Activity
| | |
Number
of Options | | |
Weighted-
Average Exercise
Price per
Share | | |
Weighted-
Average Remaining Contractual Term
(years) | |
| Outstanding at September 30, 2025 | |
| 245,215 | | |
$ | 48.50 | | |
| | |
| Exercised | |
| (32,353 | ) | |
| 1.70 | | |
| | |
| Forfeited | |
| (1,124 | ) | |
| 68.40 | | |
| | |
| Expired | |
| (1,417 | ) | |
| 50.60 | | |
| | |
| Outstanding at March 31, 2026 | |
| 210,321 | | |
| 55.59 | | |
| 5.4 | |
| Exercisable at March 31, 2026 | |
| 205,448 | | |
| 55.29 | | |
| 5.4 | |
|
Stock
option activity for the year ended September 30, 2025 is as follows:
Schedule of Stock Option Activity
| | |
Number of
Options | | |
Weighted-
Average
Exercise Price
per Share | | |
Weighted-
Average
Remaining
Contractual
Term
(years) | |
| Outstanding at September 30, 2024 | |
| 274,063 | | |
$ | 48.90 | | |
| | |
| Forfeited | |
| (7,154 | ) | |
| 60.30 | | |
| | |
| Expired | |
| (21,691 | ) | |
| 49.20 | | |
| | |
| Outstanding at September 30, 2025 | |
| 245,218 | | |
| 48.50 | | |
| 5.9 | |
| Exercisable at September 30, 2025 | |
| 233,102 | | |
| 47.50 | | |
| 5.8 | |
|
| Schedule of Consolidated Statements of Operations and Comprehensive Loss |
The
condensed consolidated statements of operations and comprehensive loss include stock-based compensation expense as follows:
Schedule of Consolidated Statements of Operations and Comprehensive Loss
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three
months ended
March
31, | | |
Six
months ended
March
31, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Cost of revenue – product | |
$ | 48 | | |
$ | 42 | | |
$ | 84 | | |
$ | 58 | |
| Cost of revenue – services | |
| 35 | | |
| — | | |
| 57 | | |
| — | |
| Research and development | |
| 19 | | |
| 65 | | |
| 109 | | |
| 146 | |
| Selling, general and administrative | |
| 2,351 | | |
| 3,245 | | |
| 7,345 | | |
| 12,950 | |
| Total stock-based compensation
expense | |
$ | 2,453 | | |
$ | 3,352 | | |
$ | 7,592 | | |
$ | 13,154 | |
|
The
consolidated statements of operations and comprehensive loss include stock-based compensation expense as follows:
Schedule of Consolidated Statements of Operations and Comprehensive Loss
| | |
| | |
| |
| | |
Year ended
September 30, | |
| | |
2025 | | |
2024 | |
| | |
| | |
| |
| Cost of revenue – product | |
$ | 174 | | |
$ | 15 | |
| Cost of revenue – services | |
| 9 | | |
| — | |
| Research and development | |
| 338 | | |
| 1,124 | |
| Selling, general and administrative | |
| 25,098 | | |
| 20,244 | |
| Total stock-based compensation expense | |
$ | 25,619 | | |
$ | 21,383 | |
|
| Schedule of Weighted-Average Grant Date Fair Value of Options Granted |
|
Schedule of Weighted-Average Grant Date Fair Value of Options Granted
| | |
Year ended September 30, 2024 | |
| | |
Range | |
| | |
Low | | |
High | |
| | |
| | |
| |
| Expected volatility | |
| 54.8 | % | |
| 55.6 | % |
| Expected dividend yield | |
| 0 | % | |
| 0 | % |
| Risk-free interest rate | |
| 3.9 | % | |
| 4.4 | % |
| Expected term (years) | |
| 4.5 | | |
| 5.3 | |
|